1
|
Wang L, Feng B, Liang M, Li D, Cong R, Chen Z, Wang S, Ma X, Zhao X. Prognostic performance of MRI LI-RADS version 2018 features and clinical-pathological factors in alpha-fetoprotein-negative hepatocellular carcinoma. Abdom Radiol (NY) 2024; 49:1918-1928. [PMID: 38642093 DOI: 10.1007/s00261-024-04278-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2023] [Revised: 03/04/2024] [Accepted: 03/05/2024] [Indexed: 04/22/2024]
Abstract
PURPOSE To evaluate the role of the magnetic resonance imaging (MRI) Liver Imaging Reporting and Data System (LI-RADS) version 2018 features and clinical-pathological factors for predicting the prognosis of alpha-fetoprotein (AFP)-negative (≤ 20 ng/ml) hepatocellular carcinoma (HCC) patients, and to compare with other traditional staging systems. METHODS We retrospectively enrolled 169 patients with AFP-negative HCC who received preoperative MRI and hepatectomy between January 2015 and August 2020 (derivation dataset:validation dataset = 118:51). A prognostic model was constructed using the risk factors identified via Cox regression analysis. Predictive performance and discrimination capability were evaluated and compared with those of two traditional staging systems. RESULTS Six risk factors, namely the LI-RADS category, blood products in mass, microvascular invasion, tumor size, cirrhosis, and albumin-bilirubin grade, were associated with recurrence-free survival. The prognostic model constructed using these factors achieved C-index of 0.705 and 0.674 in the derivation and validation datasets, respectively. Furthermore, the model performed better in predicting patient prognosis than traditional staging systems. The model effectively stratified patients with AFP-negative HCC into high- and low-risk groups with significantly different outcomes (p < 0.05). CONCLUSION A prognostic model integrating the LI-RADS category, blood products in mass, microvascular invasion, tumor size, cirrhosis, and albumin-bilirubin grade may serve as a valuable tool for refining risk stratification in patients with AFP-negative HCC.
Collapse
Affiliation(s)
- Leyao Wang
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| | - Bing Feng
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| | - Meng Liang
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| | - Dengfeng Li
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| | - Rong Cong
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| | - Zhaowei Chen
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China
| | - Sicong Wang
- Magnetic Resonance Imaging Research, General Electric Healthcare (China), Beijing, 100176, China
| | - Xiaohong Ma
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
| | - Xinming Zhao
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
| |
Collapse
|
2
|
Lee JH, Hwang JA, Gu K, Shin J, Han S, Kim YK. Magnetic resonance elastography as a preoperative assessment for predicting intrahepatic recurrence in patients with hepatocellular carcinoma. Magn Reson Imaging 2024; 109:127-133. [PMID: 38513784 DOI: 10.1016/j.mri.2024.03.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2024] [Revised: 03/03/2024] [Accepted: 03/13/2024] [Indexed: 03/23/2024]
Abstract
PURPOSE Magnetic resonance elastography (MRE) is a noninvasive tool for diagnosing hepatic fibrosis with high accuracy. We investigated the preoperative clinical and imaging predictors of intrahepatic recurrence after curative resection of hepatocellular carcinoma (HCC), and evaluated MRE as a predictor of intrahepatic recurrence. METHODS We retrospectively evaluated 80 patients who underwent preoperative contrast-enhanced magnetic resonance imaging (MRI) with two-dimensional MRE and curative resection for treatment-naïve HCC between May 2019 and December 2021. Liver stiffness (LS) was measured on the elastograms, and the optimal cutoff of LS for predicting intrahepatic recurrence was obtained using receiver operating characteristic (ROC) analysis. An LS above this cutoff was defined as MRE-recurrence. Preoperative imaging features of the tumor were assessed on MRI, including features in the Liver Imaging Reporting and Data System and microvascular invasion (MVI). Recurrence-free survival (RFS) rates were estimated using the Kaplan-Meier method, and differences were compared using the log-rank test. Using a Cox proportional hazards model, we conducted a multivariable analysis to investigate the factors affecting recurrence-free survival. RESULTS During a median follow-up period of 32 months (range, 4-52 months), thirteen patients (16.3%) developed intrahepatic recurrence. ROC analysis determined an LS cutoff of ≥4.35 kPa to define MRE-recurrence. The 4-year RFS rate was significantly higher in patients without MRE-recurrence than in those with MRE-recurrence (93.4% vs. 48.9%; p = 0.001). In multivariable analysis, MRE-recurrence (Hazard ratio [HR], 5.9; 95% confidence interval [CI], 1.5-23.1) and MVI (HR, 3.4; 95% CI, 1.0-11.3) were independent predictors of intrahepatic recurrence. CONCLUSIONS Patients without MRE-recurrence had significantly higher RFS rates than those with MRE-recurrence. MRE-recurrence and MVI were independent predictors of intrahepatic recurrence in patients after curative resection for HCC.
Collapse
Affiliation(s)
- Jeong Hyun Lee
- Department of Radiology and Center for Imaging Sciences, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - Jeong Ah Hwang
- Department of Radiology and Center for Imaging Sciences, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
| | - Kyowon Gu
- Department of Radiology and Center for Imaging Sciences, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - Jaeseung Shin
- Department of Radiology and Center for Imaging Sciences, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - Seungchul Han
- Department of Radiology and Center for Imaging Sciences, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - Young Kon Kim
- Department of Radiology and Center for Imaging Sciences, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| |
Collapse
|
3
|
Lu Y, Cen Y, He X, Mo X, Luo F, Zhong Y. Magnetic resonance imaging-based rim enhancement could effectually predict poor prognosis in hepatocellular carcinoma: a meta-analysis. Eur J Gastroenterol Hepatol 2024; 36:505-512. [PMID: 38555599 PMCID: PMC10965130 DOI: 10.1097/meg.0000000000002727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Accepted: 09/06/2023] [Indexed: 04/02/2024]
Abstract
Recent studies have initially shown that MRI-based rim enhancement associates with poor prognosis in hepatocellular carcinoma (HCC) patients, but their sample sizes are small, leading to a necessary of comprehensive analyses to make a relatively solid statement. Thus, this meta-analysis aimed to summarize the correlation between MRI-based rim enhancement and prognosis in HCC patients. Until March 2023, a literature search was conducted on Web of Science, PubMed, EMBASE, Cochrane, CNKI, Wangfang, and CQVIP databases in order to identify studies that report the correlation between MRI-based rim enhancement and the prognosis of HCC patients. MRI-based rim enhancement and prognostic data were extracted and analyzed. In our study, eight studies containing 1816 HCC patients were analyzed. Generally, the presence of MRI-based rim enhancement was related to shortened disease-free survival (DFS) [hazard ratio (HR): 2.77, 95% confidence interval (CI): 2.11-3.62, P < 0.001], and worse overall survival (OS) (HR: 5.43, 95% CI: 2.14-13.79, P < 0.001). While no other prognostic data could be retrieved. Funnel plots, Begg's test, and Egger's test all indicated that no publication bias existed; and the risk score by Newcastle-Ottawa Scale criteria ranged from 7-9 points, suggesting a generally low risk of bias. Meanwhile, the sensitivity analysis showed that the significant findings did not change by omitting each study. Then, subgroup analyses revealed that no matter stratified by tumor size, treatment option, or sample size, rim enhancement was linked with unsatisfied DFS (all P < 0.05). Conclusively, MRI-based rim enhancement could effectually estimate poor survival in HCC patients, indicating its good prognostic value.
Collapse
Affiliation(s)
- Yumin Lu
- Department of Radiology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, China
| | - Yongyi Cen
- Department of Radiology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, China
| | - Xin He
- Department of Radiology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, China
| | - Xiaping Mo
- Department of Radiology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, China
| | - Fang Luo
- Department of Radiology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, China
| | - Yubao Zhong
- Department of Radiology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, China
| |
Collapse
|
4
|
Chernyak V. Editorial for "Diagnostic Model for Proliferative HCC Using LI-RADS: Assessing Therapeutic Outcomes in Hepatectomy and TKI-ICI Combination". J Magn Reson Imaging 2024. [PMID: 38682725 DOI: 10.1002/jmri.29402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2024] [Accepted: 04/04/2024] [Indexed: 05/01/2024] Open
Affiliation(s)
- Victoria Chernyak
- Department of Radiology, Memorial Sloan Kettering Cancer Center NYC, New York, New York, USA
| |
Collapse
|
5
|
Kartalis N, Grigoriadis A. LI-RADS in Patients with Solitary Resected Hepatocellular Carcinoma: Glancing beyond Diagnosis. Radiology 2024; 310:e240161. [PMID: 38411516 DOI: 10.1148/radiol.240161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/28/2024]
Affiliation(s)
- Nikolaos Kartalis
- From the Division of Radiology, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, and Department of Radiology Huddinge, Karolinska University Hospital, O-huset 42, 14186 Stockholm, Sweden
| | - Aristeidis Grigoriadis
- From the Division of Radiology, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska Institutet, and Department of Radiology Huddinge, Karolinska University Hospital, O-huset 42, 14186 Stockholm, Sweden
| |
Collapse
|
6
|
Cannella R, Matteini F, Dioguardi Burgio M, Sartoris R, Beaufrère A, Calderaro J, Mulé S, Reizine E, Luciani A, Laurent A, Seror O, Ganne-Carrié N, Wagner M, Scatton O, Vilgrain V, Cauchy F, Hobeika C, Ronot M. Association of LI-RADS and Histopathologic Features with Survival in Patients with Solitary Resected Hepatocellular Carcinoma. Radiology 2024; 310:e231160. [PMID: 38411519 DOI: 10.1148/radiol.231160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/28/2024]
Abstract
Background Both Liver Imaging Reporting and Data System (LI-RADS) and histopathologic features provide prognostic information in patients with hepatocellular carcinoma (HCC), but whether LI-RADS is independently associated with survival is uncertain. Purpose To assess the association of LI-RADS categories and features with survival outcomes in patients with solitary resected HCC. Materials and Methods This retrospective study included patients with solitary resected HCC from three institutions examined with preoperative contrast-enhanced CT and/or MRI between January 2008 and December 2019. Three independent readers evaluated the LI-RADS version 2018 categories and features. Histopathologic features including World Health Organization tumor grade, microvascular and macrovascular invasion, satellite nodules, and tumor capsule were recorded. Overall survival and disease-free survival were assessed with Cox regression models. Marginal effects of nontargetoid features on survival were estimated using propensity score matching. Results A total of 360 patients (median age, 64 years [IQR, 56-70 years]; 280 male patients) were included. At CT and MRI, the LI-RADS LR-M category was associated with increased risk of recurrence (CT: hazard ratio [HR] = 1.83 [95% CI: 1.26, 2.66], P = .001; MRI: HR = 2.22 [95% CI: 1.56, 3.16], P < .001) and death (CT: HR = 2.47 [95% CI: 1.72, 3.55], P < .001; MRI: HR = 1.80 [95% CI: 1.32, 2.46], P < .001) independently of histopathologic features. The presence of at least one nontargetoid feature was associated with an increased risk of recurrence (CT: HR = 1.80 [95% CI: 1.36, 2.38], P < .001; MRI: HR = 1.93 [95% CI: 1.81, 2.06], P < .001) and death (CT: HR = 1.51 [95% CI: 1.10, 2.07], P < .010) independently of histopathologic features. In matched samples, recurrence was associated with the presence of at least one nontargetoid feature at CT (HR = 2.06 [95% CI: 1.15, 3.66]; P = .02) or MRI (HR = 1.79 [95% CI: 1.01, 3.20]; P = .048). Conclusion In patients with solitary resected HCC, LR-M category and nontargetoid features were negatively associated with survival independently of histopathologic characteristics. © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Kartalis and Grigoriadis in this issue.
Collapse
Affiliation(s)
- Roberto Cannella
- From the Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy (R.C., F.M.); Departments of Radiology (F.M., M.D.B., R.S., V.V., M.R.), Pathology (A.B.), and Hepatobiliary Surgery (F.C., C.H.), Hôpital Beaujon, AP-HP Nord, 100 Blvd du Général Leclerc, 92118 Clichy, France; Université Paris Cité, Paris, France (A.B., V.V., M.R.); Centre de Recherche sur l'Inflammation, INSERM UMR 1149, Paris, France (A.B.); Departments of Pathology (J.C.), Medical Imaging (S.M., E.R., A. Luciani), and Hepatobiliary and Digestive Surgery (A. Laurent), Hôpitaux Universitaires Henri-Mondor, AP-HP, Université Paris Est Créteil, Faculté de Santé, Créteil, France; INSERM U955, Team "Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers," Créteil, France (A. Laurent); Department of Radiology (O. Seror) and Liver Unit (N.G.C.), Avicenne Hospital, AP-HP, Bobigny, France; Sorbonne Paris Nord University, UFR SMBH, Bobigny, France (N.G.C.); INSERM UMR 1138, Team "Functional Genomic of Solid Tumors," Paris, France (N.G.C.); and Departments of Imaging (M.W.) and HPB and Liver Transplantation (O. Scatton), Hôpital Universitaire Pitié-Salpêtrière, AP-HP, Sorbonne Université, Centre de Recherche Saint-Antoine INSERM, Paris, France
| | - Francesco Matteini
- From the Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy (R.C., F.M.); Departments of Radiology (F.M., M.D.B., R.S., V.V., M.R.), Pathology (A.B.), and Hepatobiliary Surgery (F.C., C.H.), Hôpital Beaujon, AP-HP Nord, 100 Blvd du Général Leclerc, 92118 Clichy, France; Université Paris Cité, Paris, France (A.B., V.V., M.R.); Centre de Recherche sur l'Inflammation, INSERM UMR 1149, Paris, France (A.B.); Departments of Pathology (J.C.), Medical Imaging (S.M., E.R., A. Luciani), and Hepatobiliary and Digestive Surgery (A. Laurent), Hôpitaux Universitaires Henri-Mondor, AP-HP, Université Paris Est Créteil, Faculté de Santé, Créteil, France; INSERM U955, Team "Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers," Créteil, France (A. Laurent); Department of Radiology (O. Seror) and Liver Unit (N.G.C.), Avicenne Hospital, AP-HP, Bobigny, France; Sorbonne Paris Nord University, UFR SMBH, Bobigny, France (N.G.C.); INSERM UMR 1138, Team "Functional Genomic of Solid Tumors," Paris, France (N.G.C.); and Departments of Imaging (M.W.) and HPB and Liver Transplantation (O. Scatton), Hôpital Universitaire Pitié-Salpêtrière, AP-HP, Sorbonne Université, Centre de Recherche Saint-Antoine INSERM, Paris, France
| | - Marco Dioguardi Burgio
- From the Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy (R.C., F.M.); Departments of Radiology (F.M., M.D.B., R.S., V.V., M.R.), Pathology (A.B.), and Hepatobiliary Surgery (F.C., C.H.), Hôpital Beaujon, AP-HP Nord, 100 Blvd du Général Leclerc, 92118 Clichy, France; Université Paris Cité, Paris, France (A.B., V.V., M.R.); Centre de Recherche sur l'Inflammation, INSERM UMR 1149, Paris, France (A.B.); Departments of Pathology (J.C.), Medical Imaging (S.M., E.R., A. Luciani), and Hepatobiliary and Digestive Surgery (A. Laurent), Hôpitaux Universitaires Henri-Mondor, AP-HP, Université Paris Est Créteil, Faculté de Santé, Créteil, France; INSERM U955, Team "Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers," Créteil, France (A. Laurent); Department of Radiology (O. Seror) and Liver Unit (N.G.C.), Avicenne Hospital, AP-HP, Bobigny, France; Sorbonne Paris Nord University, UFR SMBH, Bobigny, France (N.G.C.); INSERM UMR 1138, Team "Functional Genomic of Solid Tumors," Paris, France (N.G.C.); and Departments of Imaging (M.W.) and HPB and Liver Transplantation (O. Scatton), Hôpital Universitaire Pitié-Salpêtrière, AP-HP, Sorbonne Université, Centre de Recherche Saint-Antoine INSERM, Paris, France
| | - Riccardo Sartoris
- From the Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy (R.C., F.M.); Departments of Radiology (F.M., M.D.B., R.S., V.V., M.R.), Pathology (A.B.), and Hepatobiliary Surgery (F.C., C.H.), Hôpital Beaujon, AP-HP Nord, 100 Blvd du Général Leclerc, 92118 Clichy, France; Université Paris Cité, Paris, France (A.B., V.V., M.R.); Centre de Recherche sur l'Inflammation, INSERM UMR 1149, Paris, France (A.B.); Departments of Pathology (J.C.), Medical Imaging (S.M., E.R., A. Luciani), and Hepatobiliary and Digestive Surgery (A. Laurent), Hôpitaux Universitaires Henri-Mondor, AP-HP, Université Paris Est Créteil, Faculté de Santé, Créteil, France; INSERM U955, Team "Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers," Créteil, France (A. Laurent); Department of Radiology (O. Seror) and Liver Unit (N.G.C.), Avicenne Hospital, AP-HP, Bobigny, France; Sorbonne Paris Nord University, UFR SMBH, Bobigny, France (N.G.C.); INSERM UMR 1138, Team "Functional Genomic of Solid Tumors," Paris, France (N.G.C.); and Departments of Imaging (M.W.) and HPB and Liver Transplantation (O. Scatton), Hôpital Universitaire Pitié-Salpêtrière, AP-HP, Sorbonne Université, Centre de Recherche Saint-Antoine INSERM, Paris, France
| | - Aurélie Beaufrère
- From the Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy (R.C., F.M.); Departments of Radiology (F.M., M.D.B., R.S., V.V., M.R.), Pathology (A.B.), and Hepatobiliary Surgery (F.C., C.H.), Hôpital Beaujon, AP-HP Nord, 100 Blvd du Général Leclerc, 92118 Clichy, France; Université Paris Cité, Paris, France (A.B., V.V., M.R.); Centre de Recherche sur l'Inflammation, INSERM UMR 1149, Paris, France (A.B.); Departments of Pathology (J.C.), Medical Imaging (S.M., E.R., A. Luciani), and Hepatobiliary and Digestive Surgery (A. Laurent), Hôpitaux Universitaires Henri-Mondor, AP-HP, Université Paris Est Créteil, Faculté de Santé, Créteil, France; INSERM U955, Team "Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers," Créteil, France (A. Laurent); Department of Radiology (O. Seror) and Liver Unit (N.G.C.), Avicenne Hospital, AP-HP, Bobigny, France; Sorbonne Paris Nord University, UFR SMBH, Bobigny, France (N.G.C.); INSERM UMR 1138, Team "Functional Genomic of Solid Tumors," Paris, France (N.G.C.); and Departments of Imaging (M.W.) and HPB and Liver Transplantation (O. Scatton), Hôpital Universitaire Pitié-Salpêtrière, AP-HP, Sorbonne Université, Centre de Recherche Saint-Antoine INSERM, Paris, France
| | - Julien Calderaro
- From the Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy (R.C., F.M.); Departments of Radiology (F.M., M.D.B., R.S., V.V., M.R.), Pathology (A.B.), and Hepatobiliary Surgery (F.C., C.H.), Hôpital Beaujon, AP-HP Nord, 100 Blvd du Général Leclerc, 92118 Clichy, France; Université Paris Cité, Paris, France (A.B., V.V., M.R.); Centre de Recherche sur l'Inflammation, INSERM UMR 1149, Paris, France (A.B.); Departments of Pathology (J.C.), Medical Imaging (S.M., E.R., A. Luciani), and Hepatobiliary and Digestive Surgery (A. Laurent), Hôpitaux Universitaires Henri-Mondor, AP-HP, Université Paris Est Créteil, Faculté de Santé, Créteil, France; INSERM U955, Team "Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers," Créteil, France (A. Laurent); Department of Radiology (O. Seror) and Liver Unit (N.G.C.), Avicenne Hospital, AP-HP, Bobigny, France; Sorbonne Paris Nord University, UFR SMBH, Bobigny, France (N.G.C.); INSERM UMR 1138, Team "Functional Genomic of Solid Tumors," Paris, France (N.G.C.); and Departments of Imaging (M.W.) and HPB and Liver Transplantation (O. Scatton), Hôpital Universitaire Pitié-Salpêtrière, AP-HP, Sorbonne Université, Centre de Recherche Saint-Antoine INSERM, Paris, France
| | - Sébastien Mulé
- From the Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy (R.C., F.M.); Departments of Radiology (F.M., M.D.B., R.S., V.V., M.R.), Pathology (A.B.), and Hepatobiliary Surgery (F.C., C.H.), Hôpital Beaujon, AP-HP Nord, 100 Blvd du Général Leclerc, 92118 Clichy, France; Université Paris Cité, Paris, France (A.B., V.V., M.R.); Centre de Recherche sur l'Inflammation, INSERM UMR 1149, Paris, France (A.B.); Departments of Pathology (J.C.), Medical Imaging (S.M., E.R., A. Luciani), and Hepatobiliary and Digestive Surgery (A. Laurent), Hôpitaux Universitaires Henri-Mondor, AP-HP, Université Paris Est Créteil, Faculté de Santé, Créteil, France; INSERM U955, Team "Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers," Créteil, France (A. Laurent); Department of Radiology (O. Seror) and Liver Unit (N.G.C.), Avicenne Hospital, AP-HP, Bobigny, France; Sorbonne Paris Nord University, UFR SMBH, Bobigny, France (N.G.C.); INSERM UMR 1138, Team "Functional Genomic of Solid Tumors," Paris, France (N.G.C.); and Departments of Imaging (M.W.) and HPB and Liver Transplantation (O. Scatton), Hôpital Universitaire Pitié-Salpêtrière, AP-HP, Sorbonne Université, Centre de Recherche Saint-Antoine INSERM, Paris, France
| | - Edouard Reizine
- From the Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy (R.C., F.M.); Departments of Radiology (F.M., M.D.B., R.S., V.V., M.R.), Pathology (A.B.), and Hepatobiliary Surgery (F.C., C.H.), Hôpital Beaujon, AP-HP Nord, 100 Blvd du Général Leclerc, 92118 Clichy, France; Université Paris Cité, Paris, France (A.B., V.V., M.R.); Centre de Recherche sur l'Inflammation, INSERM UMR 1149, Paris, France (A.B.); Departments of Pathology (J.C.), Medical Imaging (S.M., E.R., A. Luciani), and Hepatobiliary and Digestive Surgery (A. Laurent), Hôpitaux Universitaires Henri-Mondor, AP-HP, Université Paris Est Créteil, Faculté de Santé, Créteil, France; INSERM U955, Team "Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers," Créteil, France (A. Laurent); Department of Radiology (O. Seror) and Liver Unit (N.G.C.), Avicenne Hospital, AP-HP, Bobigny, France; Sorbonne Paris Nord University, UFR SMBH, Bobigny, France (N.G.C.); INSERM UMR 1138, Team "Functional Genomic of Solid Tumors," Paris, France (N.G.C.); and Departments of Imaging (M.W.) and HPB and Liver Transplantation (O. Scatton), Hôpital Universitaire Pitié-Salpêtrière, AP-HP, Sorbonne Université, Centre de Recherche Saint-Antoine INSERM, Paris, France
| | - Alain Luciani
- From the Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy (R.C., F.M.); Departments of Radiology (F.M., M.D.B., R.S., V.V., M.R.), Pathology (A.B.), and Hepatobiliary Surgery (F.C., C.H.), Hôpital Beaujon, AP-HP Nord, 100 Blvd du Général Leclerc, 92118 Clichy, France; Université Paris Cité, Paris, France (A.B., V.V., M.R.); Centre de Recherche sur l'Inflammation, INSERM UMR 1149, Paris, France (A.B.); Departments of Pathology (J.C.), Medical Imaging (S.M., E.R., A. Luciani), and Hepatobiliary and Digestive Surgery (A. Laurent), Hôpitaux Universitaires Henri-Mondor, AP-HP, Université Paris Est Créteil, Faculté de Santé, Créteil, France; INSERM U955, Team "Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers," Créteil, France (A. Laurent); Department of Radiology (O. Seror) and Liver Unit (N.G.C.), Avicenne Hospital, AP-HP, Bobigny, France; Sorbonne Paris Nord University, UFR SMBH, Bobigny, France (N.G.C.); INSERM UMR 1138, Team "Functional Genomic of Solid Tumors," Paris, France (N.G.C.); and Departments of Imaging (M.W.) and HPB and Liver Transplantation (O. Scatton), Hôpital Universitaire Pitié-Salpêtrière, AP-HP, Sorbonne Université, Centre de Recherche Saint-Antoine INSERM, Paris, France
| | - Alexis Laurent
- From the Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy (R.C., F.M.); Departments of Radiology (F.M., M.D.B., R.S., V.V., M.R.), Pathology (A.B.), and Hepatobiliary Surgery (F.C., C.H.), Hôpital Beaujon, AP-HP Nord, 100 Blvd du Général Leclerc, 92118 Clichy, France; Université Paris Cité, Paris, France (A.B., V.V., M.R.); Centre de Recherche sur l'Inflammation, INSERM UMR 1149, Paris, France (A.B.); Departments of Pathology (J.C.), Medical Imaging (S.M., E.R., A. Luciani), and Hepatobiliary and Digestive Surgery (A. Laurent), Hôpitaux Universitaires Henri-Mondor, AP-HP, Université Paris Est Créteil, Faculté de Santé, Créteil, France; INSERM U955, Team "Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers," Créteil, France (A. Laurent); Department of Radiology (O. Seror) and Liver Unit (N.G.C.), Avicenne Hospital, AP-HP, Bobigny, France; Sorbonne Paris Nord University, UFR SMBH, Bobigny, France (N.G.C.); INSERM UMR 1138, Team "Functional Genomic of Solid Tumors," Paris, France (N.G.C.); and Departments of Imaging (M.W.) and HPB and Liver Transplantation (O. Scatton), Hôpital Universitaire Pitié-Salpêtrière, AP-HP, Sorbonne Université, Centre de Recherche Saint-Antoine INSERM, Paris, France
| | - Olivier Seror
- From the Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy (R.C., F.M.); Departments of Radiology (F.M., M.D.B., R.S., V.V., M.R.), Pathology (A.B.), and Hepatobiliary Surgery (F.C., C.H.), Hôpital Beaujon, AP-HP Nord, 100 Blvd du Général Leclerc, 92118 Clichy, France; Université Paris Cité, Paris, France (A.B., V.V., M.R.); Centre de Recherche sur l'Inflammation, INSERM UMR 1149, Paris, France (A.B.); Departments of Pathology (J.C.), Medical Imaging (S.M., E.R., A. Luciani), and Hepatobiliary and Digestive Surgery (A. Laurent), Hôpitaux Universitaires Henri-Mondor, AP-HP, Université Paris Est Créteil, Faculté de Santé, Créteil, France; INSERM U955, Team "Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers," Créteil, France (A. Laurent); Department of Radiology (O. Seror) and Liver Unit (N.G.C.), Avicenne Hospital, AP-HP, Bobigny, France; Sorbonne Paris Nord University, UFR SMBH, Bobigny, France (N.G.C.); INSERM UMR 1138, Team "Functional Genomic of Solid Tumors," Paris, France (N.G.C.); and Departments of Imaging (M.W.) and HPB and Liver Transplantation (O. Scatton), Hôpital Universitaire Pitié-Salpêtrière, AP-HP, Sorbonne Université, Centre de Recherche Saint-Antoine INSERM, Paris, France
| | - Nathalie Ganne-Carrié
- From the Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy (R.C., F.M.); Departments of Radiology (F.M., M.D.B., R.S., V.V., M.R.), Pathology (A.B.), and Hepatobiliary Surgery (F.C., C.H.), Hôpital Beaujon, AP-HP Nord, 100 Blvd du Général Leclerc, 92118 Clichy, France; Université Paris Cité, Paris, France (A.B., V.V., M.R.); Centre de Recherche sur l'Inflammation, INSERM UMR 1149, Paris, France (A.B.); Departments of Pathology (J.C.), Medical Imaging (S.M., E.R., A. Luciani), and Hepatobiliary and Digestive Surgery (A. Laurent), Hôpitaux Universitaires Henri-Mondor, AP-HP, Université Paris Est Créteil, Faculté de Santé, Créteil, France; INSERM U955, Team "Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers," Créteil, France (A. Laurent); Department of Radiology (O. Seror) and Liver Unit (N.G.C.), Avicenne Hospital, AP-HP, Bobigny, France; Sorbonne Paris Nord University, UFR SMBH, Bobigny, France (N.G.C.); INSERM UMR 1138, Team "Functional Genomic of Solid Tumors," Paris, France (N.G.C.); and Departments of Imaging (M.W.) and HPB and Liver Transplantation (O. Scatton), Hôpital Universitaire Pitié-Salpêtrière, AP-HP, Sorbonne Université, Centre de Recherche Saint-Antoine INSERM, Paris, France
| | - Mathilde Wagner
- From the Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy (R.C., F.M.); Departments of Radiology (F.M., M.D.B., R.S., V.V., M.R.), Pathology (A.B.), and Hepatobiliary Surgery (F.C., C.H.), Hôpital Beaujon, AP-HP Nord, 100 Blvd du Général Leclerc, 92118 Clichy, France; Université Paris Cité, Paris, France (A.B., V.V., M.R.); Centre de Recherche sur l'Inflammation, INSERM UMR 1149, Paris, France (A.B.); Departments of Pathology (J.C.), Medical Imaging (S.M., E.R., A. Luciani), and Hepatobiliary and Digestive Surgery (A. Laurent), Hôpitaux Universitaires Henri-Mondor, AP-HP, Université Paris Est Créteil, Faculté de Santé, Créteil, France; INSERM U955, Team "Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers," Créteil, France (A. Laurent); Department of Radiology (O. Seror) and Liver Unit (N.G.C.), Avicenne Hospital, AP-HP, Bobigny, France; Sorbonne Paris Nord University, UFR SMBH, Bobigny, France (N.G.C.); INSERM UMR 1138, Team "Functional Genomic of Solid Tumors," Paris, France (N.G.C.); and Departments of Imaging (M.W.) and HPB and Liver Transplantation (O. Scatton), Hôpital Universitaire Pitié-Salpêtrière, AP-HP, Sorbonne Université, Centre de Recherche Saint-Antoine INSERM, Paris, France
| | - Olivier Scatton
- From the Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy (R.C., F.M.); Departments of Radiology (F.M., M.D.B., R.S., V.V., M.R.), Pathology (A.B.), and Hepatobiliary Surgery (F.C., C.H.), Hôpital Beaujon, AP-HP Nord, 100 Blvd du Général Leclerc, 92118 Clichy, France; Université Paris Cité, Paris, France (A.B., V.V., M.R.); Centre de Recherche sur l'Inflammation, INSERM UMR 1149, Paris, France (A.B.); Departments of Pathology (J.C.), Medical Imaging (S.M., E.R., A. Luciani), and Hepatobiliary and Digestive Surgery (A. Laurent), Hôpitaux Universitaires Henri-Mondor, AP-HP, Université Paris Est Créteil, Faculté de Santé, Créteil, France; INSERM U955, Team "Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers," Créteil, France (A. Laurent); Department of Radiology (O. Seror) and Liver Unit (N.G.C.), Avicenne Hospital, AP-HP, Bobigny, France; Sorbonne Paris Nord University, UFR SMBH, Bobigny, France (N.G.C.); INSERM UMR 1138, Team "Functional Genomic of Solid Tumors," Paris, France (N.G.C.); and Departments of Imaging (M.W.) and HPB and Liver Transplantation (O. Scatton), Hôpital Universitaire Pitié-Salpêtrière, AP-HP, Sorbonne Université, Centre de Recherche Saint-Antoine INSERM, Paris, France
| | - Valérie Vilgrain
- From the Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy (R.C., F.M.); Departments of Radiology (F.M., M.D.B., R.S., V.V., M.R.), Pathology (A.B.), and Hepatobiliary Surgery (F.C., C.H.), Hôpital Beaujon, AP-HP Nord, 100 Blvd du Général Leclerc, 92118 Clichy, France; Université Paris Cité, Paris, France (A.B., V.V., M.R.); Centre de Recherche sur l'Inflammation, INSERM UMR 1149, Paris, France (A.B.); Departments of Pathology (J.C.), Medical Imaging (S.M., E.R., A. Luciani), and Hepatobiliary and Digestive Surgery (A. Laurent), Hôpitaux Universitaires Henri-Mondor, AP-HP, Université Paris Est Créteil, Faculté de Santé, Créteil, France; INSERM U955, Team "Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers," Créteil, France (A. Laurent); Department of Radiology (O. Seror) and Liver Unit (N.G.C.), Avicenne Hospital, AP-HP, Bobigny, France; Sorbonne Paris Nord University, UFR SMBH, Bobigny, France (N.G.C.); INSERM UMR 1138, Team "Functional Genomic of Solid Tumors," Paris, France (N.G.C.); and Departments of Imaging (M.W.) and HPB and Liver Transplantation (O. Scatton), Hôpital Universitaire Pitié-Salpêtrière, AP-HP, Sorbonne Université, Centre de Recherche Saint-Antoine INSERM, Paris, France
| | - François Cauchy
- From the Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy (R.C., F.M.); Departments of Radiology (F.M., M.D.B., R.S., V.V., M.R.), Pathology (A.B.), and Hepatobiliary Surgery (F.C., C.H.), Hôpital Beaujon, AP-HP Nord, 100 Blvd du Général Leclerc, 92118 Clichy, France; Université Paris Cité, Paris, France (A.B., V.V., M.R.); Centre de Recherche sur l'Inflammation, INSERM UMR 1149, Paris, France (A.B.); Departments of Pathology (J.C.), Medical Imaging (S.M., E.R., A. Luciani), and Hepatobiliary and Digestive Surgery (A. Laurent), Hôpitaux Universitaires Henri-Mondor, AP-HP, Université Paris Est Créteil, Faculté de Santé, Créteil, France; INSERM U955, Team "Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers," Créteil, France (A. Laurent); Department of Radiology (O. Seror) and Liver Unit (N.G.C.), Avicenne Hospital, AP-HP, Bobigny, France; Sorbonne Paris Nord University, UFR SMBH, Bobigny, France (N.G.C.); INSERM UMR 1138, Team "Functional Genomic of Solid Tumors," Paris, France (N.G.C.); and Departments of Imaging (M.W.) and HPB and Liver Transplantation (O. Scatton), Hôpital Universitaire Pitié-Salpêtrière, AP-HP, Sorbonne Université, Centre de Recherche Saint-Antoine INSERM, Paris, France
| | - Christian Hobeika
- From the Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy (R.C., F.M.); Departments of Radiology (F.M., M.D.B., R.S., V.V., M.R.), Pathology (A.B.), and Hepatobiliary Surgery (F.C., C.H.), Hôpital Beaujon, AP-HP Nord, 100 Blvd du Général Leclerc, 92118 Clichy, France; Université Paris Cité, Paris, France (A.B., V.V., M.R.); Centre de Recherche sur l'Inflammation, INSERM UMR 1149, Paris, France (A.B.); Departments of Pathology (J.C.), Medical Imaging (S.M., E.R., A. Luciani), and Hepatobiliary and Digestive Surgery (A. Laurent), Hôpitaux Universitaires Henri-Mondor, AP-HP, Université Paris Est Créteil, Faculté de Santé, Créteil, France; INSERM U955, Team "Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers," Créteil, France (A. Laurent); Department of Radiology (O. Seror) and Liver Unit (N.G.C.), Avicenne Hospital, AP-HP, Bobigny, France; Sorbonne Paris Nord University, UFR SMBH, Bobigny, France (N.G.C.); INSERM UMR 1138, Team "Functional Genomic of Solid Tumors," Paris, France (N.G.C.); and Departments of Imaging (M.W.) and HPB and Liver Transplantation (O. Scatton), Hôpital Universitaire Pitié-Salpêtrière, AP-HP, Sorbonne Université, Centre de Recherche Saint-Antoine INSERM, Paris, France
| | - Maxime Ronot
- From the Section of Radiology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy (R.C., F.M.); Departments of Radiology (F.M., M.D.B., R.S., V.V., M.R.), Pathology (A.B.), and Hepatobiliary Surgery (F.C., C.H.), Hôpital Beaujon, AP-HP Nord, 100 Blvd du Général Leclerc, 92118 Clichy, France; Université Paris Cité, Paris, France (A.B., V.V., M.R.); Centre de Recherche sur l'Inflammation, INSERM UMR 1149, Paris, France (A.B.); Departments of Pathology (J.C.), Medical Imaging (S.M., E.R., A. Luciani), and Hepatobiliary and Digestive Surgery (A. Laurent), Hôpitaux Universitaires Henri-Mondor, AP-HP, Université Paris Est Créteil, Faculté de Santé, Créteil, France; INSERM U955, Team "Pathophysiology and Therapy of Chronic Viral Hepatitis and Related Cancers," Créteil, France (A. Laurent); Department of Radiology (O. Seror) and Liver Unit (N.G.C.), Avicenne Hospital, AP-HP, Bobigny, France; Sorbonne Paris Nord University, UFR SMBH, Bobigny, France (N.G.C.); INSERM UMR 1138, Team "Functional Genomic of Solid Tumors," Paris, France (N.G.C.); and Departments of Imaging (M.W.) and HPB and Liver Transplantation (O. Scatton), Hôpital Universitaire Pitié-Salpêtrière, AP-HP, Sorbonne Université, Centre de Recherche Saint-Antoine INSERM, Paris, France
| |
Collapse
|
7
|
Min JH, Lee MW, Rhim H, Han S, Song KD, Kang TW, Jeong WK, Cha DI, Kim JM, Choi GS, Kim K. LI-RADS category is associated with treatment outcomes of small single HCC: surgical resection vs. radiofrequency ablation. Eur Radiol 2024; 34:525-537. [PMID: 37526668 DOI: 10.1007/s00330-023-09998-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2023] [Revised: 05/31/2023] [Accepted: 06/05/2023] [Indexed: 08/02/2023]
Abstract
OBJECTIVES To assess whether the Liver Imaging Reporting and Data System (LI-RADS) category is associated with the treatment outcomes of small single hepatocellular carcinoma (HCC) after surgical resection (SR) and radiofrequency ablation (RFA). METHODS This retrospective study included 357 patients who underwent SR (n = 209) or RFA (n = 148) for a single HCC of ≤ 3 cm between 2014 and 2016. LI-RADS categories were assigned. Overall survival (OS), recurrence-free survival (RFS), and local tumor progression (LTP) rates after treatment were compared according to the LI-RADS category (LR-4/5 vs. LR-M) before and after propensity score matching (PSM). Prognostic factors for treatment outcomes were assessed. RESULTS In total, 357 patients (mean age, 59 years; men, 272) with 357 HCCs (294 LR-4/5 and 63 LR-M) were included. After PSM (n = 78 in each treatment group), there were 10 and 11 LR-M HCCs in the SR and RFA group, respectively. There were no significant differences in OS or RFS. However, SR provided a lower 5-year LTP rate than RFA (1.4% vs. 14.9%, p = 0.001). SR provided a lower 5-year LTP rate than RFA for LR-M HCCs (0% vs. 34.4%, p = 0.062) and LR-4/5 HCCs (1.5% vs. 12.0%, p = 0.008). The LI-RADS category was the sole risk factor associated with poor OS (hazard ratio [HR] 3.79, p = 0.004), RFS (HR 2.12; p = 0.001), and LTP (HR 2.89; p = 0.032). CONCLUSION LI-RADS classification is associated with the treatment outcome of HCC, supporting favorable outcomes of SR over RFA for LTP, especially for HCCs categorized as LR-M. CLINICAL RELEVANCE STATEMENT Liver Imaging Reporting and Data System category has a potential prognostic role, supporting favorable outcomes of surgical resection over radiofrequency ablation for local tumor progression, especially for hepatocellular carcinoma categorized as LR-M. KEY POINTS • SR provided a lower 5-year LTP rate than RFA for HCCs categorized as LR-M (0% vs. 34.4%, p = 0.062) and HCCs categorized as LR-4/5 (1.5% vs. 12.0%, p = 0.008). • There is a steeply increased risk of LTP within 1 year after RFA for LR-M HCCs, compared to SR. • The LI-RADS category was the sole risk factor associated with poor OS (HR 3.79, p = 0.004), RFS (HR 2.12; p = 0.001), and LTP (HR 2.89; p = 0.032) in patients with HCC of ≤ 3 cm treated with SR or RFA.
Collapse
Affiliation(s)
- Ji Hye Min
- Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro Gangnam-gu, Seoul, 06351, Republic of Korea
| | - Min Woo Lee
- Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro Gangnam-gu, Seoul, 06351, Republic of Korea.
- Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, 81 Irwon-Ro Gangnam-gu, Seoul, 06351, Republic of Korea.
| | - Hyunchul Rhim
- Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro Gangnam-gu, Seoul, 06351, Republic of Korea
| | - Seungchul Han
- Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro Gangnam-gu, Seoul, 06351, Republic of Korea
| | - Kyoung Doo Song
- Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro Gangnam-gu, Seoul, 06351, Republic of Korea
| | - Tae Wook Kang
- Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro Gangnam-gu, Seoul, 06351, Republic of Korea
| | - Woo Kyoung Jeong
- Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro Gangnam-gu, Seoul, 06351, Republic of Korea
| | - Dong Ik Cha
- Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro Gangnam-gu, Seoul, 06351, Republic of Korea
| | - Jong Man Kim
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - Gyu Seong Choi
- Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - Kyunga Kim
- Biomedical Statistics Center, Research Institute for Future Medicine, Samsung Medical Center, Seoul, Republic of Korea
| |
Collapse
|
8
|
Wang L, Liang M, Feng B, Li D, Cong R, Chen Z, Wang S, Ma X, Zhao X. Microvascular invasion-negative hepatocellular carcinoma: Prognostic value of qualitative and quantitative Gd-EOB-DTPA MRI analysis. Eur J Radiol 2023; 168:111146. [PMID: 37832198 DOI: 10.1016/j.ejrad.2023.111146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2023] [Revised: 09/27/2023] [Accepted: 10/06/2023] [Indexed: 10/15/2023]
Abstract
OBJECTIVES The purpose of this study was to establish a model for predicting the prognosis of patients with microvascular invasion (MVI)-negative hepatocellular carcinoma (HCC) based on qualitative and quantitative analyses of Gd-EOB-DTPA magnetic resonance imaging (MRI). MATERIALS AND METHODS Consecutive patients with MVI-negative HCC who underwent preoperative Gd-EOB-DTPA MRI between January 2015 and December 2019 were retrospectively enrolled.In total, 122 patients were randomly assigned to the training and validation groups at a ratio of 7:3. Univariate and multivariate logistic regression analyses were performed to identify significant clinical parameters and MRI features, including quantitative and qualitative parameters associated with prognosis, which were incorporated into a predictive nomogram. The end-point of this study was recurrence-free survival. Outcomes were compared between groups using the Kaplan-Meier method with the log-rank test. RESULTS During a median follow-up period of 58.86 months, 38 patients (31.15 %) experienced recurrence. Multivariate analysis revealed that lower relative enhancement ratio (RER), hepatobiliary phase hypointensity without arterial phase hyperenhancement, Liver Imaging Reporting and Data System category, mild-moderate T2 hyperintensity, and higher aspartate aminotransferase levels were risk factors associated with prognosis and then incorporated into the prognostic model. C-indices for training and validation groups were 0.732 and 0.692, respectively. The most appropriate cut-off value for RER was 1.197. Patients with RER ≤ 1.197 had significantly higher postoperative recurrence rates than those with RER > 1.197 (p = 0.004). CONCLUSION The model integrating qualitative and quantitative imaging parameters and clinical parameters satisfactorily predicted the prognosis of patients with MVI-negative HCC.
Collapse
Affiliation(s)
- Leyao Wang
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Meng Liang
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Bing Feng
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Dengfeng Li
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Rong Cong
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Zhaowei Chen
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
| | - Sicong Wang
- Sicong Wang, Magnetic Resonance Imaging Research, General Electric Healthcare (China), Beijing 100176, China
| | - Xiaohong Ma
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
| | - Xinming Zhao
- Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
| |
Collapse
|
9
|
Goins SM, Adamo RG, Lam E, Costa AF, van der Pol CB, Salameh JP, Dawit H, McInnes MDF, Bashir MR. Conversion Strategy for LI-RADS Category 5 Observations across Versions 2014, 2017, and 2018. Radiology 2023; 307:e222971. [PMID: 37129488 DOI: 10.1148/radiol.222971] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Affiliation(s)
- Stacy M Goins
- From the Department of Radiology, Duke University School of Medicine, Durham, NC (S.M.G.); Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada (R.G.A.); The Ottawa Hospital Research Insitute, Clinical Epidemiology Program, Ottawa, ON, Canada (E.L., M.D.F.M.); Clinical Epidemiology Program (H.D.), and University of Ottawa Departments of Radiology and Epidemiology (M.D.F.M.), Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Diagnostic Radiology, Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada (A.F.C.); Department of Diagnostic Radiology, Dalhousie University, Halifax, NS, Canada (A.F.C.); Juravinski Hospital and Cancer Centre, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada (C.B.v.d.P.); Faculty of Health Sciences, Queen's University, Kingston, ON, Canada (J.P.S.); Departments of Radiology and Medicine and Center for Advanced Magnetic Resonance Development, Duke University Medical Center, 2301 Erwin Rd, Durham, NC 27701 (M.R.B.); and Department of Radiology, University of North Carolina, Chapel Hill, NC (M.R.B.)
| | - Robert G Adamo
- From the Department of Radiology, Duke University School of Medicine, Durham, NC (S.M.G.); Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada (R.G.A.); The Ottawa Hospital Research Insitute, Clinical Epidemiology Program, Ottawa, ON, Canada (E.L., M.D.F.M.); Clinical Epidemiology Program (H.D.), and University of Ottawa Departments of Radiology and Epidemiology (M.D.F.M.), Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Diagnostic Radiology, Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada (A.F.C.); Department of Diagnostic Radiology, Dalhousie University, Halifax, NS, Canada (A.F.C.); Juravinski Hospital and Cancer Centre, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada (C.B.v.d.P.); Faculty of Health Sciences, Queen's University, Kingston, ON, Canada (J.P.S.); Departments of Radiology and Medicine and Center for Advanced Magnetic Resonance Development, Duke University Medical Center, 2301 Erwin Rd, Durham, NC 27701 (M.R.B.); and Department of Radiology, University of North Carolina, Chapel Hill, NC (M.R.B.)
| | - Eric Lam
- From the Department of Radiology, Duke University School of Medicine, Durham, NC (S.M.G.); Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada (R.G.A.); The Ottawa Hospital Research Insitute, Clinical Epidemiology Program, Ottawa, ON, Canada (E.L., M.D.F.M.); Clinical Epidemiology Program (H.D.), and University of Ottawa Departments of Radiology and Epidemiology (M.D.F.M.), Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Diagnostic Radiology, Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada (A.F.C.); Department of Diagnostic Radiology, Dalhousie University, Halifax, NS, Canada (A.F.C.); Juravinski Hospital and Cancer Centre, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada (C.B.v.d.P.); Faculty of Health Sciences, Queen's University, Kingston, ON, Canada (J.P.S.); Departments of Radiology and Medicine and Center for Advanced Magnetic Resonance Development, Duke University Medical Center, 2301 Erwin Rd, Durham, NC 27701 (M.R.B.); and Department of Radiology, University of North Carolina, Chapel Hill, NC (M.R.B.)
| | - Andreu F Costa
- From the Department of Radiology, Duke University School of Medicine, Durham, NC (S.M.G.); Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada (R.G.A.); The Ottawa Hospital Research Insitute, Clinical Epidemiology Program, Ottawa, ON, Canada (E.L., M.D.F.M.); Clinical Epidemiology Program (H.D.), and University of Ottawa Departments of Radiology and Epidemiology (M.D.F.M.), Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Diagnostic Radiology, Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada (A.F.C.); Department of Diagnostic Radiology, Dalhousie University, Halifax, NS, Canada (A.F.C.); Juravinski Hospital and Cancer Centre, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada (C.B.v.d.P.); Faculty of Health Sciences, Queen's University, Kingston, ON, Canada (J.P.S.); Departments of Radiology and Medicine and Center for Advanced Magnetic Resonance Development, Duke University Medical Center, 2301 Erwin Rd, Durham, NC 27701 (M.R.B.); and Department of Radiology, University of North Carolina, Chapel Hill, NC (M.R.B.)
| | - Christian B van der Pol
- From the Department of Radiology, Duke University School of Medicine, Durham, NC (S.M.G.); Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada (R.G.A.); The Ottawa Hospital Research Insitute, Clinical Epidemiology Program, Ottawa, ON, Canada (E.L., M.D.F.M.); Clinical Epidemiology Program (H.D.), and University of Ottawa Departments of Radiology and Epidemiology (M.D.F.M.), Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Diagnostic Radiology, Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada (A.F.C.); Department of Diagnostic Radiology, Dalhousie University, Halifax, NS, Canada (A.F.C.); Juravinski Hospital and Cancer Centre, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada (C.B.v.d.P.); Faculty of Health Sciences, Queen's University, Kingston, ON, Canada (J.P.S.); Departments of Radiology and Medicine and Center for Advanced Magnetic Resonance Development, Duke University Medical Center, 2301 Erwin Rd, Durham, NC 27701 (M.R.B.); and Department of Radiology, University of North Carolina, Chapel Hill, NC (M.R.B.)
| | - Jean-Paul Salameh
- From the Department of Radiology, Duke University School of Medicine, Durham, NC (S.M.G.); Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada (R.G.A.); The Ottawa Hospital Research Insitute, Clinical Epidemiology Program, Ottawa, ON, Canada (E.L., M.D.F.M.); Clinical Epidemiology Program (H.D.), and University of Ottawa Departments of Radiology and Epidemiology (M.D.F.M.), Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Diagnostic Radiology, Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada (A.F.C.); Department of Diagnostic Radiology, Dalhousie University, Halifax, NS, Canada (A.F.C.); Juravinski Hospital and Cancer Centre, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada (C.B.v.d.P.); Faculty of Health Sciences, Queen's University, Kingston, ON, Canada (J.P.S.); Departments of Radiology and Medicine and Center for Advanced Magnetic Resonance Development, Duke University Medical Center, 2301 Erwin Rd, Durham, NC 27701 (M.R.B.); and Department of Radiology, University of North Carolina, Chapel Hill, NC (M.R.B.)
| | - Haben Dawit
- From the Department of Radiology, Duke University School of Medicine, Durham, NC (S.M.G.); Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada (R.G.A.); The Ottawa Hospital Research Insitute, Clinical Epidemiology Program, Ottawa, ON, Canada (E.L., M.D.F.M.); Clinical Epidemiology Program (H.D.), and University of Ottawa Departments of Radiology and Epidemiology (M.D.F.M.), Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Diagnostic Radiology, Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada (A.F.C.); Department of Diagnostic Radiology, Dalhousie University, Halifax, NS, Canada (A.F.C.); Juravinski Hospital and Cancer Centre, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada (C.B.v.d.P.); Faculty of Health Sciences, Queen's University, Kingston, ON, Canada (J.P.S.); Departments of Radiology and Medicine and Center for Advanced Magnetic Resonance Development, Duke University Medical Center, 2301 Erwin Rd, Durham, NC 27701 (M.R.B.); and Department of Radiology, University of North Carolina, Chapel Hill, NC (M.R.B.)
| | - Matthew D F McInnes
- From the Department of Radiology, Duke University School of Medicine, Durham, NC (S.M.G.); Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada (R.G.A.); The Ottawa Hospital Research Insitute, Clinical Epidemiology Program, Ottawa, ON, Canada (E.L., M.D.F.M.); Clinical Epidemiology Program (H.D.), and University of Ottawa Departments of Radiology and Epidemiology (M.D.F.M.), Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Diagnostic Radiology, Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada (A.F.C.); Department of Diagnostic Radiology, Dalhousie University, Halifax, NS, Canada (A.F.C.); Juravinski Hospital and Cancer Centre, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada (C.B.v.d.P.); Faculty of Health Sciences, Queen's University, Kingston, ON, Canada (J.P.S.); Departments of Radiology and Medicine and Center for Advanced Magnetic Resonance Development, Duke University Medical Center, 2301 Erwin Rd, Durham, NC 27701 (M.R.B.); and Department of Radiology, University of North Carolina, Chapel Hill, NC (M.R.B.)
| | - Mustafa R Bashir
- From the Department of Radiology, Duke University School of Medicine, Durham, NC (S.M.G.); Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada (R.G.A.); The Ottawa Hospital Research Insitute, Clinical Epidemiology Program, Ottawa, ON, Canada (E.L., M.D.F.M.); Clinical Epidemiology Program (H.D.), and University of Ottawa Departments of Radiology and Epidemiology (M.D.F.M.), Ottawa Hospital Research Institute, Ottawa, ON, Canada; Department of Diagnostic Radiology, Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada (A.F.C.); Department of Diagnostic Radiology, Dalhousie University, Halifax, NS, Canada (A.F.C.); Juravinski Hospital and Cancer Centre, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada (C.B.v.d.P.); Faculty of Health Sciences, Queen's University, Kingston, ON, Canada (J.P.S.); Departments of Radiology and Medicine and Center for Advanced Magnetic Resonance Development, Duke University Medical Center, 2301 Erwin Rd, Durham, NC 27701 (M.R.B.); and Department of Radiology, University of North Carolina, Chapel Hill, NC (M.R.B.)
| |
Collapse
|
10
|
Chernyak V, Fowler KJ, Do RKG, Kamaya A, Kono Y, Tang A, Mitchell DG, Weinreb J, Santillan CS, Sirlin CB. LI-RADS: Looking Back, Looking Forward. Radiology 2023; 307:e222801. [PMID: 36853182 PMCID: PMC10068888 DOI: 10.1148/radiol.222801] [Citation(s) in RCA: 13] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Revised: 01/09/2023] [Accepted: 01/23/2023] [Indexed: 03/01/2023]
Abstract
Since its initial release in 2011, the Liver Imaging Reporting and Data System (LI-RADS) has evolved and expanded in scope. It started as a single algorithm for hepatocellular carcinoma (HCC) diagnosis with CT or MRI with extracellular contrast agents and has grown into a multialgorithm network covering all major liver imaging modalities and contexts of use. Furthermore, it has developed its own lexicon, report templates, and supplementary materials. This article highlights the major achievements of LI-RADS in the past 11 years, including adoption in clinical care and research across the globe, and complete unification of HCC diagnostic systems in the United States. Additionally, the authors discuss current gaps in knowledge, which include challenges in surveillance, diagnostic population definition, perceived complexity, limited sensitivity of LR-5 (definite HCC) category, management implications of indeterminate observations, challenges in reporting, and treatment response assessment following radiation-based therapies and systemic treatments. Finally, the authors discuss future directions, which will focus on mitigating the current challenges and incorporating advanced technologies. Tha authors envision that LI-RADS will ultimately transform into a probability-based system for diagnosis and prognostication of liver cancers that will integrate patient characteristics and quantitative imaging features, while accounting for imaging modality and contrast agent.
Collapse
Affiliation(s)
- Victoria Chernyak
- From the Department of Radiology, Memorial Sloan-Kettering Cancer
Center, New York, NY (V.C., R.K.G.D.); Liver Imaging Group, Department of
Radiology, University of California, San Diego, San Diego, Calif (K.J.F.,
C.S.S., C.B.S.); Department of Radiology, Stanford University Medical Center,
Stanford, Calif (A.K.); Department of Medicine and Radiology, University of
California, San Diego, San Diego, Calif (Y.K.); Department of Radiology,
Radiation Oncology and Nuclear Medicine, Université de Montréal,
Montréal, Canada (A.T.); Department of Radiology, Thomas Jefferson
University Hospital, Philadelphia, Pa (D.G.M.); and Department of Radiology,
Yale Medical School, New Haven, Conn (J.W.)
| | - Kathryn J. Fowler
- From the Department of Radiology, Memorial Sloan-Kettering Cancer
Center, New York, NY (V.C., R.K.G.D.); Liver Imaging Group, Department of
Radiology, University of California, San Diego, San Diego, Calif (K.J.F.,
C.S.S., C.B.S.); Department of Radiology, Stanford University Medical Center,
Stanford, Calif (A.K.); Department of Medicine and Radiology, University of
California, San Diego, San Diego, Calif (Y.K.); Department of Radiology,
Radiation Oncology and Nuclear Medicine, Université de Montréal,
Montréal, Canada (A.T.); Department of Radiology, Thomas Jefferson
University Hospital, Philadelphia, Pa (D.G.M.); and Department of Radiology,
Yale Medical School, New Haven, Conn (J.W.)
| | - Richard K. G. Do
- From the Department of Radiology, Memorial Sloan-Kettering Cancer
Center, New York, NY (V.C., R.K.G.D.); Liver Imaging Group, Department of
Radiology, University of California, San Diego, San Diego, Calif (K.J.F.,
C.S.S., C.B.S.); Department of Radiology, Stanford University Medical Center,
Stanford, Calif (A.K.); Department of Medicine and Radiology, University of
California, San Diego, San Diego, Calif (Y.K.); Department of Radiology,
Radiation Oncology and Nuclear Medicine, Université de Montréal,
Montréal, Canada (A.T.); Department of Radiology, Thomas Jefferson
University Hospital, Philadelphia, Pa (D.G.M.); and Department of Radiology,
Yale Medical School, New Haven, Conn (J.W.)
| | - Aya Kamaya
- From the Department of Radiology, Memorial Sloan-Kettering Cancer
Center, New York, NY (V.C., R.K.G.D.); Liver Imaging Group, Department of
Radiology, University of California, San Diego, San Diego, Calif (K.J.F.,
C.S.S., C.B.S.); Department of Radiology, Stanford University Medical Center,
Stanford, Calif (A.K.); Department of Medicine and Radiology, University of
California, San Diego, San Diego, Calif (Y.K.); Department of Radiology,
Radiation Oncology and Nuclear Medicine, Université de Montréal,
Montréal, Canada (A.T.); Department of Radiology, Thomas Jefferson
University Hospital, Philadelphia, Pa (D.G.M.); and Department of Radiology,
Yale Medical School, New Haven, Conn (J.W.)
| | - Yuko Kono
- From the Department of Radiology, Memorial Sloan-Kettering Cancer
Center, New York, NY (V.C., R.K.G.D.); Liver Imaging Group, Department of
Radiology, University of California, San Diego, San Diego, Calif (K.J.F.,
C.S.S., C.B.S.); Department of Radiology, Stanford University Medical Center,
Stanford, Calif (A.K.); Department of Medicine and Radiology, University of
California, San Diego, San Diego, Calif (Y.K.); Department of Radiology,
Radiation Oncology and Nuclear Medicine, Université de Montréal,
Montréal, Canada (A.T.); Department of Radiology, Thomas Jefferson
University Hospital, Philadelphia, Pa (D.G.M.); and Department of Radiology,
Yale Medical School, New Haven, Conn (J.W.)
| | - An Tang
- From the Department of Radiology, Memorial Sloan-Kettering Cancer
Center, New York, NY (V.C., R.K.G.D.); Liver Imaging Group, Department of
Radiology, University of California, San Diego, San Diego, Calif (K.J.F.,
C.S.S., C.B.S.); Department of Radiology, Stanford University Medical Center,
Stanford, Calif (A.K.); Department of Medicine and Radiology, University of
California, San Diego, San Diego, Calif (Y.K.); Department of Radiology,
Radiation Oncology and Nuclear Medicine, Université de Montréal,
Montréal, Canada (A.T.); Department of Radiology, Thomas Jefferson
University Hospital, Philadelphia, Pa (D.G.M.); and Department of Radiology,
Yale Medical School, New Haven, Conn (J.W.)
| | - Donald G. Mitchell
- From the Department of Radiology, Memorial Sloan-Kettering Cancer
Center, New York, NY (V.C., R.K.G.D.); Liver Imaging Group, Department of
Radiology, University of California, San Diego, San Diego, Calif (K.J.F.,
C.S.S., C.B.S.); Department of Radiology, Stanford University Medical Center,
Stanford, Calif (A.K.); Department of Medicine and Radiology, University of
California, San Diego, San Diego, Calif (Y.K.); Department of Radiology,
Radiation Oncology and Nuclear Medicine, Université de Montréal,
Montréal, Canada (A.T.); Department of Radiology, Thomas Jefferson
University Hospital, Philadelphia, Pa (D.G.M.); and Department of Radiology,
Yale Medical School, New Haven, Conn (J.W.)
| | - Jeffrey Weinreb
- From the Department of Radiology, Memorial Sloan-Kettering Cancer
Center, New York, NY (V.C., R.K.G.D.); Liver Imaging Group, Department of
Radiology, University of California, San Diego, San Diego, Calif (K.J.F.,
C.S.S., C.B.S.); Department of Radiology, Stanford University Medical Center,
Stanford, Calif (A.K.); Department of Medicine and Radiology, University of
California, San Diego, San Diego, Calif (Y.K.); Department of Radiology,
Radiation Oncology and Nuclear Medicine, Université de Montréal,
Montréal, Canada (A.T.); Department of Radiology, Thomas Jefferson
University Hospital, Philadelphia, Pa (D.G.M.); and Department of Radiology,
Yale Medical School, New Haven, Conn (J.W.)
| | - Cynthia S. Santillan
- From the Department of Radiology, Memorial Sloan-Kettering Cancer
Center, New York, NY (V.C., R.K.G.D.); Liver Imaging Group, Department of
Radiology, University of California, San Diego, San Diego, Calif (K.J.F.,
C.S.S., C.B.S.); Department of Radiology, Stanford University Medical Center,
Stanford, Calif (A.K.); Department of Medicine and Radiology, University of
California, San Diego, San Diego, Calif (Y.K.); Department of Radiology,
Radiation Oncology and Nuclear Medicine, Université de Montréal,
Montréal, Canada (A.T.); Department of Radiology, Thomas Jefferson
University Hospital, Philadelphia, Pa (D.G.M.); and Department of Radiology,
Yale Medical School, New Haven, Conn (J.W.)
| | - Claude B. Sirlin
- From the Department of Radiology, Memorial Sloan-Kettering Cancer
Center, New York, NY (V.C., R.K.G.D.); Liver Imaging Group, Department of
Radiology, University of California, San Diego, San Diego, Calif (K.J.F.,
C.S.S., C.B.S.); Department of Radiology, Stanford University Medical Center,
Stanford, Calif (A.K.); Department of Medicine and Radiology, University of
California, San Diego, San Diego, Calif (Y.K.); Department of Radiology,
Radiation Oncology and Nuclear Medicine, Université de Montréal,
Montréal, Canada (A.T.); Department of Radiology, Thomas Jefferson
University Hospital, Philadelphia, Pa (D.G.M.); and Department of Radiology,
Yale Medical School, New Haven, Conn (J.W.)
| |
Collapse
|
11
|
Park SH, Kim B, Kim S, Park S, Park YH, Shin SK, Sung PS, Choi JI. Estimating postsurgical outcomes of patients with a single hepatocellular carcinoma using gadoxetic acid-enhanced MRI: risk scoring system development and validation. Eur Radiol 2023; 33:3566-3579. [PMID: 36933020 DOI: 10.1007/s00330-023-09539-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2022] [Revised: 12/14/2022] [Accepted: 02/06/2023] [Indexed: 03/19/2023]
Abstract
OBJECTIVES To develop and validate risk scoring systems using gadoxetic acid-enhanced liver MRI features and clinical factors that predict recurrence-free survival (RFS) of a single hepatocellular carcinoma (HCC). METHODS Consecutive 295 patients with treatment-naïve single HCC who underwent curative surgery were retrospectively enrolled from two centers. Cox proportional hazard models developed risk scoring systems whose discriminatory powers were validated using external data and compared to the Barcelona Clinic Liver Cancer (BCLC) or American Joint Committee on Cancer (AJCC) staging systems using Harrell's C-index. RESULTS Independent variables-tumor size (per cm; hazard ratio [HR], 1.07; 95% confidence interval [CI]: 1.02-1.13; p = 0.005), targetoid appearance (HR, 1.74; 95% CI: 1.07-2.83; p = 0.025), radiologic tumor in vein or tumor vascular invasion (HR, 2.59; 95% CI: 1.69-3.97; p < 0.001), the presence of a nonhypervascular hypointense nodule on the hepatobiliary phase (HR, 4.65; 95% CI: 3.03-7.14; p < 0.001), and pathologic macrovascular invasion (HR, 2.60; 95% CI: 1.51-4.48; p = 0.001)-with tumor markers (AFP ≥ 206 ng/mL or PIVKA-II ≥ 419 mAU/mL) derived pre- and postoperative risk scoring systems. The risk scores showed comparably good discriminatory powers in the validation set (C-index, 0.75-0.82) and outperformed the BCLC (C-index, 0.61) and AJCC staging systems (C-index, 0.58; ps < 0.05). The preoperative scoring system stratified the patients into low-, intermediate-, and high-risk for recurrence, whose 2-year recurrence rate was 3.3%, 31.8%, and 85.7%, respectively. CONCLUSION The developed and validated pre- and postoperative risk scoring systems can estimate RFS after surgery for a single HCC. KEY POINTS • The risk scoring systems predicted RFS better than the BCLC and AJCC staging systems (C-index, 0.75-0.82 vs. 0.58-0.61; ps < 0.05). • Five variables-tumor size, targetoid appearance, radiologic tumor in vein or vascular invasion, the presence of a nonhypervascular hypointense nodule on the hepatobiliary phase, and pathologic macrovascular invasion-combined with tumor markers derived risk scoring systems predicting postsurgical RFS for a single HCC. • In the risk scoring system using preoperatively-available factors, patients were classified into three distinct risk groups, with 2-year recurrence rates in the low-, intermediate-, and high-risk groups being 3.3%, 31.8%, and 85.7% in the validation set.
Collapse
Affiliation(s)
- So Hyun Park
- Department of Radiology, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea
| | - Bohyun Kim
- Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpodae-ro, Seocho-Gu, 06591, Seoul, Korea.
| | - Sehee Kim
- Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, Seoul, Korea
| | - Suyoung Park
- Department of Radiology, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea
| | - Yeon Ho Park
- Department of Surgery, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea
| | - Seung Kak Shin
- Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea
| | - Pil Soo Sung
- Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
| | - Joon-Il Choi
- Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222 Banpodae-ro, Seocho-Gu, 06591, Seoul, Korea
| |
Collapse
|
12
|
Risk stratification of solitary hepatocellular carcinoma ≤ 5 cm without microvascular invasion: prognostic values of MR imaging features based on LI-RADS and clinical parameters. Eur Radiol 2023; 33:3592-3603. [PMID: 36884087 DOI: 10.1007/s00330-023-09484-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2022] [Revised: 02/05/2023] [Accepted: 02/07/2023] [Indexed: 03/09/2023]
Abstract
OBJECTIVES To estimate the potential of preoperative MR imaging features and clinical parameters in the risk stratification of patients with solitary hepatocellular carcinoma (HCC) ≤ 5 cm without microvascular invasion (MVI) after hepatectomy. METHODS The study enrolled 166 patients with histopathological confirmed MVI-negative HCC retrospectively. The MR imaging features were evaluated by two radiologists independently. The risk factors associated with recurrence-free survival (RFS) were identified by univariate Cox regression analysis and the least absolute shrinkage and selection operator Cox regression analysis. A predictive nomogram was developed based on these risk factors, and the performance was tested in the validation cohort. The RFS was analyzed by using the Kaplan-Meier survival curves and log-rank test. RESULTS Among the 166 patients with solitary MVI-negative HCC, 86 patients presented with postoperative recurrence. Multivariate Cox regression analysis indicated that cirrhosis, tumor size, hepatitis, albumin, arterial phase hyperenhancement (APHE), washout, and mosaic architecture were risk factors associated with poor RFS and then incorporated into the nomogram. The nomogram achieved good performance with C-index values of 0.713 and 0.707 in the development and validation cohorts, respectively. Furthermore, patients were stratified into high- and low-risk subgroups, and significant prognostic differences were found between the different subgroups in both cohorts (p < 0.001 and p = 0.024, respectively). CONCLUSION The nomogram incorporated preoperative MR imaging features, and clinical parameters can be a simple and reliable tool for predicting RFS and achieving risk stratification in patients with solitary MVI-negative HCC. KEY POINTS • Application of preoperative MR imaging features and clinical parameters can effectively predict RFS in patients with solitary MVI-negative HCC. • Risk factors including cirrhosis, tumor size, hepatitis, albumin, APHE, washout, and mosaic architecture were associated with worse prognosis in patients with solitary MVI-negative HCC. • Based on the nomogram incorporating these risk factors, the MVI-negative HCC patients could be stratified into two subgroups with significant different prognoses.
Collapse
|
13
|
Hwang SH, Rhee H. Radiologic features of hepatocellular carcinoma related to prognosis. JOURNAL OF LIVER CANCER 2023; 23:143-156. [PMID: 37384030 PMCID: PMC10202237 DOI: 10.17998/jlc.2023.02.16] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/31/2022] [Revised: 01/29/2023] [Accepted: 02/16/2023] [Indexed: 06/30/2023]
Abstract
The cross-sectional imaging findings play a crucial role in the diagnosis of hepatocellular carcinoma (HCC). Recent studies have shown that imaging findings of HCC are not only relevant for the diagnosis of HCC, but also for identifying genetic and pathologic characteristics and determining prognosis. Imaging findings such as rim arterial phase hyperenhancement, arterial phase peritumoral hyperenhancement, hepatobiliary phase peritumoral hypointensity, non-smooth tumor margin, low apparent diffusion coefficient, and the LR-M category of the Liver Imaging-Reporting and Data System have been reported to be associated with poor prognosis. In contrast, imaging findings such as enhancing capsule appearance, hepatobiliary phase hyperintensity, and fat in mass have been reported to be associated with a favorable prognosis. Most of these imaging findings were examined in retrospective, single-center studies that were not adequately validated. However, the imaging findings can be applied for deciding the treatment strategy for HCC, if their significance can be confirmed by a large multicenter study. In this literature, we would like to review imaging findings related to the prognosis of HCC as well as their associated clinicopathological characteristics.
Collapse
Affiliation(s)
- Shin Hye Hwang
- Department of Radiology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea
| | - Hyungjin Rhee
- Department of Radiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
- Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
- Center for Clinical Imaging Data Science, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
| |
Collapse
|
14
|
Wang R, Xu H, Chen W, Jin L, Ma Z, Wen L, Wang H, Cao K, Du X, Li M. Gadoxetic acid-enhanced MRI with a focus on LI-RADS v2018 imaging features predicts the prognosis after radiofrequency ablation in small hepatocellular carcinoma. Front Oncol 2023; 13:975216. [PMID: 36816925 PMCID: PMC9932892 DOI: 10.3389/fonc.2023.975216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Accepted: 01/12/2023] [Indexed: 02/05/2023] Open
Abstract
Introduction Gadoxetic acid-enhanced magnetic resonance imaging (MRI) contributes to evaluating the prognosis of small hepatocellular carcinoma (sHCC) following treatment. We have investigated the potential role of gadoxetic acid-enhanced MRI based on LI-RADS (Liver Imaging Reporting and Data System) v2018 imaging features in the prognosis prediction of patients with sHCC treated with radiofrequency ablation (RFA) as the first-line treatment and formulated a predictive nomogram. Methods A total of 204 patients with sHCC who all received RFA as the first-line therapy were enrolled. All patients had undergone gadoxetic acid-enhanced MRI examinations before RFA. Uni- and multivariable analyses for RFS were assessing using a Cox proportional hazards model. A novel nomogram was further constructed for predicting RFS. The clinical capacity of the model was validated according to calibration curves, the concordance index (C-index), and decision curve analyses. Results Alpha fetoprotein (AFP) > 100 ng/ml (HR, 2.006; 95% CI, 1.111-3.621; P = 0.021), rim arterial phase hyperenhancement (APHE) (HR, 2.751; 95% CI, 1.511-5.011; P = 0.001), and targetoid restriction on diffusion-weighted imaging (DWI) (HR, 3.289; 95% CI, 1.832-5.906; P < 0.001) were considered as the independent risk features for recurrence in patients with sHCC treated with RFA. The calibration curves and C-indexes (C-index values of 0.758 and 0.807) showed the superior predictive performance of the integrated nomogram in both the training and validation groups. Discussion The gadoxetic acid-enhanced MRI features based on LI-RADS v2018, including rim APHE, targetoid restriction on DWI, and the AFP level, are the independent risk factors of recurrence in patients with sHCC treated with RFA as the first-line therapy. The predictive clinical-radiological nomogram model was constructed for clinicians to develop individualized treatment and surveillance strategies.
Collapse
Affiliation(s)
- Ruizhi Wang
- Department of Radiology, Huadong Hospital, Fudan University, Shanghai, China
| | - Hengtian Xu
- Department of Radiology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China
| | - Wufei Chen
- Department of Radiology, Huadong Hospital, Fudan University, Shanghai, China
| | - Liang Jin
- Department of Radiology, Huadong Hospital, Fudan University, Shanghai, China
| | - Zhuangxuan Ma
- Department of Radiology, Huadong Hospital, Fudan University, Shanghai, China
| | - Lei Wen
- Department of Radiology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China
| | - Hongwei Wang
- Department of General Surgery, Huadong Hospital, Fudan University, Shanghai, China
| | - Kun Cao
- Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, China
| | - Xia Du
- Department of Radiology, The Affiliated Hospital of Guizhou Medical University, Guiyang, China,*Correspondence: Xia Du, ; Ming Li,
| | - Ming Li
- Department of Radiology, Huadong Hospital, Fudan University, Shanghai, China,*Correspondence: Xia Du, ; Ming Li,
| |
Collapse
|
15
|
Wei H, Yang T, Chen J, Duan T, Jiang H, Song B. Prognostic implications of CT/MRI LI-RADS in hepatocellular carcinoma: State of the art and future directions. Liver Int 2022; 42:2131-2144. [PMID: 35808845 DOI: 10.1111/liv.15362] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/17/2022] [Revised: 06/13/2022] [Accepted: 07/05/2022] [Indexed: 02/05/2023]
Abstract
Hepatocellular carcinoma (HCC) is the fourth most lethal malignancy with an increasing incidence worldwide. Management of HCC has followed several clinical staging systems that rely on tumour morphologic characteristics and clinical variables. However, these algorithms are unlikely to profile the full landscape of tumour aggressiveness and allow accurate prognosis stratification. Noninvasive imaging biomarkers on computed tomography (CT) or magnetic resonance imaging (MRI) exhibit a promising prospect to refine the prognostication of HCC. The Liver Imaging Reporting and Data System (LI-RADS) is a comprehensive system for standardizing the terminology, techniques, interpretation, reporting and data collection of liver imaging. At present, it has been widely accepted as an effective diagnostic system for HCC in at-risk patients. Emerging data have provided new insights into the potential of CT/MRI LI-RADS in HCC prognostication, which may help refine the prognostic paradigm of HCC that promises to direct individualized management and improve patient outcomes. Therefore, this review aims to summarize several prognostic imaging features at CT/MRI for patients with HCC; the available evidence regarding the use of LI-RDAS for evaluation of tumour biology and clinical outcomes, pitfalls of current literature, and future directions for LI-RADS in the management of HCC.
Collapse
Affiliation(s)
- Hong Wei
- Department of Radiology, West China Hospital, Sichuan University, Chengdu, China
| | - Ting Yang
- Department of Radiology, West China Hospital, Sichuan University, Chengdu, China
| | - Jie Chen
- Department of Radiology, West China Hospital, Sichuan University, Chengdu, China
| | - Ting Duan
- Department of Radiology, West China Hospital, Sichuan University, Chengdu, China
| | - Hanyu Jiang
- Department of Radiology, West China Hospital, Sichuan University, Chengdu, China
| | - Bin Song
- Department of Radiology, West China Hospital, Sichuan University, Chengdu, China.,Department of Radiology, Sanya People's Hospital, Sanya, China
| |
Collapse
|
16
|
Park SH, Han K. How to Clearly and Accurately Report Odds Ratio and Hazard Ratio in Diagnostic Research Studies? Korean J Radiol 2022; 23:777-784. [PMID: 35695319 PMCID: PMC9340231 DOI: 10.3348/kjr.2022.0249] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2022] [Accepted: 04/11/2022] [Indexed: 01/17/2023] Open
Affiliation(s)
- Seong Ho Park
- Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
| | - Kyunghwa Han
- Department of Radiology, Research Institute of Radiological Science and Center for Clinical Imaging Data Science, Yonsei University College of Medicine, Seoul, Korea
| |
Collapse
|
17
|
Yang H, Han P, Huang M, Yue X, Wu L, Li X, Fan W, Li Q, Ma G, Lei P. The role of gadoxetic acid-enhanced MRI features for predicting microvascular invasion in patients with hepatocellular carcinoma. Abdom Radiol (NY) 2022; 47:948-956. [PMID: 34962593 DOI: 10.1007/s00261-021-03392-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2021] [Revised: 12/16/2021] [Accepted: 12/17/2021] [Indexed: 12/24/2022]
Abstract
OBJECTIVE To evaluate the predictive value of gadoxetic acid-enhanced MRI features (focused on Liver Imaging Reporting and Data System (LI-RADS) v2018 features and non-LI-RADS imaging features) for microvascular invasion (MVI) of hepatocellular carcinoma (HCC). METHODS From October 2018 to December 2020, 134 patients who underwent gadoxetic acid-enhanced MRI with a pathological diagnosis of HCC after hepatectomy were enrolled in this retrospective study. Two radiologists assessed the pre-hepatectomy LI-RADS v2018 imaging features and non-LI-RADS features to identify independent predictors of MVI of HCC with a logistic regression model. RESULTS Four MRI features were found to be independent predictors of MVI: corona enhancement [odds ratio (OR) 5.787; 95% confidence interval (CI) 1.180, 28.369; p = 0.030], mosaic architecture (OR 7.097; 95% CI 1.299, 38.783; p = 0.024), nonsmooth tumor margin (OR 13.131; 95% CI 3.950, 43.649; p < 0.001), and peritumoral hypointensity on hepatobiliary phase (HBP) (OR 33.123; 95% CI 2.897, 378.688; p = 0.005). When one of four imaging features was present, the sensitivity was 93.2% (41/44), and the specificity was 71.1% (64/90). CONCLUSION The four imaging features including corona enhancement, mosaic architecture, nonsmooth tumor margin, and peritumoral hypointensity on HBP can be used as preoperative imaging biomarkers for predicting MVI in patients at high risk for HCC. When one of the four imaging features is present, MVI can be predicted with a sensitivity > 90%.
Collapse
Affiliation(s)
- Hongli Yang
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Ping Han
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Mengting Huang
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Xiaofei Yue
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Linxia Wu
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Xin Li
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Wenliang Fan
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Qian Li
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Guina Ma
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China
| | - Ping Lei
- Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
- Hubei Province Key Laboratory of Molecular Imaging, Wuhan, 430022, China.
| |
Collapse
|